Key facts
- It has raised $41.5M; the latest was Later Stage VC ($13.7M) in Jan 2025.
- Notable investors include Zhuhai Gree Financial Investment, Fosun Health Capital, Tahoe Venture, WuXi AppTec, Zhuhai Gree Venture Capital Company.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ConjuStar
- ·The full record, as it builds
Funding rounds
No funding rounds for ConjuStar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ConjuStar
Researcher and developer of peptide-drug conjugate intended for oncology treatments. The company researches and develops peptide-drug conjugate (PDC) that could be widely used in clinical treatments through self-developed R&D pipeline, enabling patients with effective and sage oncology treatments.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Website
- conjustar.com/
- Ownership
- Privately Held (backing)
ConjuStar doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ConjuStar shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ConjuStar in its N-PORT filings yet. We sweep new filings monthly.